siRNA Biotech ADARx Raises $446M in 2026’s Third-Largest Biotech IPO
September 29, 2026
Source: drugdu
33
On September 24, San Diego-based siRNA therapeutics company ADARx Pharmaceuticals priced an upsized IPO of 26.25 million shares at $17.00 per share (top of the $15-$17 range), raising $446.3 million—the third-largest biotech IPO of 2026. Shares began trading on Nasdaq on September 25 under ticker ADRX.
ADARx's lead asset onvuzosiran targets hereditary angioedema (HAE), with topline data from the pivotal Phase 3 STOP-HAE trial expected by late 2027. Partner AbbVie also invested approximately $89 million in a concurrent private placement, taking a 4.9% stake. The IPO underscores continued capital market enthusiasm for RNAi therapeutics in 2026.
Source: https://www.globenewswire.com/news-release/2026/09/24/3368818/0/en/adarx-pharmaceuticals-announces-pricing-of-upsized-446-3-million-initial-public-offering.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Novo Nordisk and Nanexa Ink Up to €1.165B Long-Acting Delivery Deal for Obesity and Diabetes September 29, 2026
- Merck and Eisai’s Welireg Plus Lenvima Approved by FDA for Previously Treated Advanced Kidney Cancer September 29, 2026
- Mirum and Incyte’s Atebrioz Wins FDA Approval for Rare Bone Disorder FOP September 29, 2026
- J&J in Talks to Sell DePuy Synthes to Apollo September 29, 2026
- APAC Leadership Transition and Cyberattack Hits Full-Year Guidance September 29, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
